Trial Profile
A Single Arm, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Prader-Willi syndrome
- Focus Registrational; Therapeutic Use
- Sponsors GeneScience Pharmaceuticals
- 19 Jun 2018 New trial record